Genetic Markers for Type 2 Diabetes Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods and therapies for type 2 diabetes (T2D) and obesity lack effective tools for early detection, risk assessment, and personalized treatment approaches, leading to delayed interventions and increased complications.
Innovation Solution
The development of novel associations between specific genes, loci, and biomarkers for T2D and obesity, enabling methods and kits for risk assessment, diagnosis, and therapy development, including molecular subtyping and modulating metabolic activity of risk genes to prevent and treat T2D-related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for type 2 diabetes and obesity, then general screening is possible, but early detection and personalized risk assessment are insufficient
Solution Approach 1:
The patent applies preliminary action by identifying and analyzing genetic markers (such as TCF7L2, PPARG, KCNJ11, CAPN10, and PPARGC1A polymorphisms) before the actual development of type 2 diabetes or obesity occurs. This allows for early risk stratification and preventive intervention, transforming the diagnostic approach from reactive to proactive by assessing genetic susceptibility in advance.
Solution Approach 2:
The patent segments the complex disease risk assessment into specific genetic marker analysis. Instead of treating diabetes and obesity as homogeneous conditions, it divides the risk assessment into distinct genetic components (multiple SNPs and polymorphisms across different genes), allowing for precise identification of individual risk profiles and enabling targeted preventive strategies.
2Adaptability or versatility
If generic treatment approaches are used for type 2 diabetes and obesity, then broad applicability is achieved, but personalized treatment efficacy is reduced
Solution Approach 1:
The patent applies local quality by tailoring treatment approaches to specific genetic profiles. Different combinations of genetic markers (TCF7L2, PPARG, KCNJ11, CAPN10, PPARGC1A polymorphisms) correspond to different pathophysiological mechanisms and treatment responses, allowing clinicians to select localized, personalized interventions rather than applying uniform treatment protocols to all patients.
Solution Approach 2:
The patent introduces dynamics into treatment by making it adaptable based on genetic findings. The treatment strategy is not static but dynamically adjusted according to the patient's specific genetic risk profile, enabling flexible modification of therapeutic approaches as new genetic information becomes available or as the disease progresses.
3Measurement precision
If comprehensive genetic analysis is performed for T2D and obesity, then diagnostic precision is improved, but test complexity and cost increase
Solution Approach 1:
The patent extracts only the most clinically relevant genetic markers from the entire genome for analysis. By focusing on specific high-impact polymorphisms in genes such as TCF7L2, PPARG, KCNJ11, CAPN10, and PPARGC1A, the test kit eliminates unnecessary complexity while retaining the diagnostic power needed for accurate risk assessment, making the test both precise and practical.
Data Source
AI summary
Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.